Platelets subvert T cell immunity against cancer via GARP-TGF axis

Science Immunology

Volumn 2, Issue 11, 2017, Pages

  Rachidi, Saleh ^a,b   Metelli, Alessandra ^a,b   Riesenberg, Brian ^a,b   Wu, Bill X ^a,b   Nelson, Michelle H ^a,b   Wallace, Caroline ^a,b   Paulos, Chrystal M ^a,b   Rubinstein, Mark P ^a,b   Garrett Mayer, Elizabeth ^a,b   Hennig, Mirko ^a   Bearden, Daniel W ^c   Yang, Yi ^a,b   Liu, Bei ^a,b   Li, Zihai ^a,b,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c National Institutes of Standards and Technology   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054550866     PISSN: None     EISSN: 24709468     Source Type: Journal    
DOI: 10.1126/sciimmunol.aai7911     Document Type: Article

References (60)

1. K. Jurk, B. E. Kehrel, Platelets: Physiology and biochemistry. Semin. Thromb. Hemost. 31, 381–392 (2005).
2. A. S. Weyrich, G. A. Zimmerman, Platelets: Signaling cells in the immune continuum. Trends Immunol. 25, 489–495 (2004).
3. R. Möhle, D. Green, M. A. S. Moore, R. L. Nachman, S. Rafii, Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. U.S.A. 94, 663–668 (1997).
4. L. J. Gay, B. Felding-Habermann, Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123–134 (2011).
5. E. Sierko, M. Z. Wojtukiewicz, Platelets and angiogenesis in malignancy. Semin. Thromb. Hemost. 30, 95–108 (2004).
6. R. L. Stone, A. M. Nick, I. A. McNeish, F. Balkwill, H. D. Han, J. Bottsford-Miller, R. Rupairmoole, G. N. Armaiz-Pena, C. V. Pecot, J. Coward, M. T. Deavers, H. G. Vasquez, D. Urbauer, C. N. Landen, W. Hu, H. Gershenson, K. Matsuo, M. M. K. Shahzad, E. R. King, I. Tekedereli, B. Ozpolat, E. H. Ahn, V. K. Bond, R. Wang, A. F. Drew, F. Gushiken, D. Lamkin, K. Collins, K. DeGeest, S. K. Lutgendorf, W. Chiu, G. Lopez-Berestein, V. Afshar-Kharghan, A. K. Sood, Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 366, 610–618 (2012).
7. S. Karpatkin, E. Pearlstein, C. Ambrogio, B. S. Coller, Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J. Clin. Invest. 81, 1012–1019 (1988).
8. D. Schumacher, B. Strilic, K. K. Sivaraj, N. Wettschureck, S. Offermanns, Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24, 130–137 (2013).
9. M. Labelle, S. Begum, R. O. Hynes, Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576–590 (2011).
10. H.-G. Kopp, T. Placke, H. R. Salih, Platelet-derived transforming growth factor- down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69, 7775–7783 (2009).
11. P. Haselmayer, L. Grosse-Hovest, P. von Landenberg, H. Schild, M. P. Radsak, TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 110, 1029–1035 (2007).
12. B. Xiang, G. Zhang, L. Guo, X.-A. Li, A. J. Morris, A. Daugherty, S. W. Whiteheart, S. S. Smyth, Z. Li, Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat. Commun. 4, 2657 (2013).
13. P. Duffau, J. Seneschal, C. Nicco, C. Richez, E. Lazaro, I. Douchet, C. Bordes, J.-F. Viallard, C. Goulvestre, J.-L. Pellegrin, B. Weil, J.-F. Moreau, F. Batteux, P. Blanco, Platelet CD154 potentiates interferon- secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci. Transl. Med. 2, 47ra63 (2010).
14. B. D. Elzey, J. Tian, R. J. Jensen, A. K. Swanson, J. R. Lees, S. R. Lentz, C. S. Stein, B. Nieswandt, Y. Wang, B. L. Davidson, T. L. Ratliff, Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 19, 9–19 (2003).
15. + dendritic cells depends on glycoprotein GPIb and complement C3. Nat. Immunol. 12, 1194–1201 (2011).
16. T. Junt, H. Schulze, Z. Chen, S. Massberg, T. Goerge, A. Krueger, D. D. Wagner, T. Graf, J. E. Italiano Jr., R. A. Shivdasani, U. H. von Andrian, Dynamic visualization of thrombopoiesis within bone marrow. Science 317, 1767–1770 (2007).
17. S. P. Jackson, Arterial thrombosis—Insidious, unpredictable and deadly. Nat. Med. 17, 1423–1436 (2011).
18. S. Offermanns, Activation of platelet function through G protein–coupled receptors. Circ. Res. 99, 1293–1304 (2006).
19. + regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 106, 13445–13450 (2009).
20. J. P. Edwards, H. Fujii, A. X. Zhou, J. Creemers, D. Unutmaz, E. M. Shevach, Regulation of the expression of GARP/latent TGF-1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation. J. Immunol. 190, 5506–5515 (2013).
21. M. Staron, S. Wu, H. Feng, A. Stojanovic, X. Du, R. Bona, B. Liu, Z. Li, Heat-shock protein gp96/grp94 is an essential chaperone for the platelet glycoprotein Ib-IX-V complex. Blood 117, 7136–7144 (2011).
22. Y. Zhang, B. X. Wu, A. Metelli, J. E. Thaxton, F. Hong, S. Rachidi, E. Ansa-Addo, S. Sun, C. Vasu, Y. Yang, B. Liu, Z. Li, GP96 is a GARP chaperone and controls regulatory T cell functions. J. Clin. Invest. 125, 859–869 (2015).
23. L. Senzel, D. V. Gnatenko, W. F. Bahou, The platelet proteome. Curr. Opin. Hematol. 16, 329–333 (2009).
24. G. L. Reed, M. L. Fitzgerald, J. Polgár, Molecular mechanisms of platelet exocytosis: Insights into the “secrete” life of thrombocytes. Blood 96, 3334–3342 (2000).
25. S. A. Rosenberg, N. P. Restifo, Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
26. P. Sharma, J. P. Allison, Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205–214 (2015).
27. P. Muranski, A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C. S. Hinrichs, K. W. Kerstann, L. Feigenbaum, C.-C. Chan, N. P. Restifo, Tumor-specific Th17–polarized cells eradicate large established melanoma. Blood 112, 362–373 (2008).
28. + T cells. J. Exp. Med. 198, 569–580 (2003).
29. + T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J. Am. Coll. Surg. 214, 700–707 (2012).
30. J. E. Murphy-Ullrich, M. Poczatek, Activation of latent TGF- by thrombospondin-1: Mechanisms and physiology. Cytokine Growth Factor Rev. 11, 59–69 (2000).
31. K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, J. Ammer, M. Edinger, E. Gottfried, S. Schwarz, G. Rothe, S. Hoves, K. Renner, B. Timischl, A. Mackensen, L. Kunz-Schughart, R. Andreesen, S. W. Krause, M. Kreutz, Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812–3819 (2007).
32. O. R. Colegio, N.-Q. Chu, A. L. Szabo, T. Chu, A. M. Rhebergen, V. Jairam, N. Cyrus, C. E. Brokowski, S. C. Eisenbarth, G. M. Phillips, G. W. Cline, A. J. Phillips, R. Medzhitov, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559–563 (2014).
33. + T-cell engraftment and antitumor immunity in lymphodepleted hosts is IL7R dependent. Cancer Immunol. Res. 3, 1364–1374 (2015).
34. R. K. Assoian, A. Komoriya, C. A. Meyers, D. M. Miller, M. B. Sporn, Transforming growth factor- in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem. 258, 7155–7160 (1983).
35. R. Wang, J. Zhu, X. Dong, M. Shi, C. Lu, T. A. Springer, GARP regulates the bioavailability and activation of TGF. Mol. Biol. Cell 23, 1129–1139 (2012).
36. J. Cuende, S. Liénart, O. Dedobbeleer, B. van der Woning, G. De Boeck, J. Stockis, C. Huygens, D. Colau, J. Somja, P. Delvenne, M. Hannon, F. Baron, L. Dumoutier, J.-C. Renauld, H. De Haard, M. Saunders, P. G. Coulie, S. Lucas, Monoclonal antibodies against GARP/TGF-1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci. Transl. Med. 7, 284ra56 (2015).
37. A. Meyer, W. Wang, J. Qu, L. Croft, J. L. Degen, B. S. Coller, J. Ahamed, Platelet TGF-1 contributions to plasma TGF-1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood 119, 1064–1074 (2012).
38. + T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. 75, 3800–3811 (2015).
39. B. Homet Moreno, J. M. Zaretsky, A. Garcia-Diaz, J. Tsoi, G. Parisi, L. Robert, K. Meeth, A. Ndoye, M. Bosenberg, A. T. Weeraratna, T. G. Graeber, B. Comin-Anduix, S. Hu-Lieskovan, A. Ribas, Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer Immunol. Res. 4, 845–857 (2016).
40. A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, S. M. Albelda, Transforming growth factor- receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966–3974 (2008).
41. J. G. Quatromoni, Y. Wang, D. D. Vo, L. F. Morris, A. R. Jazirehi, W. McBride, T. Chatila, R. C. Koya, J. S. Economou, T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGF) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J. Transl. Med. 10, 127 (2012).
42. L. Zhang, Z. Yu, P. Muranski, D. C. Palmer, N. P. Restifo, S. A. Rosenberg, R. A. Morgan, Inhibition of TGF- signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 20, 575–580 (2013).
43. A. D. Michelson, Antiplatelet therapies for the treatment of cardiovascular disease. Nat. Rev. Drug Discov. 9, 154–169 (2010).
44. H. Zhou, E. C. Gabazza, H. Takeya, H. Deguchi, H. Urano, Y. Adachi, K. Suzuki, Prothrombin and its derivatives stimulate motility of melanoma cells. Thromb. Haemost. 80, 407–412 (1998).
45. L. Erpenbeck, M. P. Schön, Deadly allies: The fatal interplay between platelets and metastasizing cancer cells. Blood 115, 3427–3436 (2010).
46. H. M. Pinedo, H. M. W. Verheul, R. J. D’Amato, J. Folkman, Involvement of platelets in tumour angiogenesis? Lancet 352, 1775–1777 (1998).
47. J. Massagué, TGF in cancer. Cell 134, 215–230 (2008).
48. G. de Gaetano, Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 86, 349–356 (2001).
49. D. J. Grainger, P. R. Kemp, J. C. Metcalfe, A. C. Liu, R. M. Lawn, N. R. Williams, A. A. Grace, P. M. Schofield, A. Chauhan, The serum concentration of active transforming growth factor- is severely depressed in advanced atherosclerosis. Nat. Med. 1, 74–79 (1995).
50. T.-H. Lin, Y.-Y. Shao, S.-Y. Chan, C.-Y. Huang, C.-H. Hsu, A.-L. Cheng, High serum transforming growth factor-1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib. Clin. Cancer Res. 21, 3678–3684 (2015).
51. S. F. Shariat, M. Shalev, A. Menesses-Diaz, I. Y. Kim, M. W. Kattan, T. M. Wheeler, K. M. Slawin, Preoperative plasma levels of transforming growth factor beta1 (TGF-1) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19, 2856–2864 (2001).
52. S. Zelenay, A. G. van der Veen, J. P. Böttcher, K. J. Snelgrove, N. Rogers, S. E. Acton, P. Chakravarty, M. R. Girotti, R. Marais, S. A. Quezada, E. Sahai, C. Reis e Sousa, Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
53. G. Sitia, R. Aiolfi, P. Di Lucia, M. Mainetti, A. Fiocchi, F. Mingozzi, A. Esposito, Z. M. Ruggeri, F. V. Chisari, M. Iannacone, L. G. Guidotti, Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc. Natl. Acad. Sci. U.S.A. 109, E2165–E2172 (2012).
54. M. G. Best, N. Sol, I. Kooi, J. Tannous, B. A. Westerman, F. Rustenburg, P. Schellen, H. Verschueren, E. Post, J. Koster, B. Ylstra, N. Ameziane, J. Dorsman, E. F. Smit, H. M. Verheul, D. P. Noske, J. C. Reijneveld, R. J. A. Nilsson, B. A. Tannous, P. Wesseling, T. Wurdinger, RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28, 666–676 (2015).
55. R. Tiedt, T. Schomber, H. Hao-Shen, R. C. Skoda, Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood 109, 1503–1506 (2007).
56. Y. Yang, B. Liu, J. Dai, P. K. Srivastava, D. J. Zammit, L. Lefrançois, Z. Li, Heat shock protein gp96 is a master chaperone for Toll-like receptors and is important in the innate function of macrophages. Immunity 26, 215–226 (2007).
57. T. L. Hwang, A. J. Shaka, Water suppression that works. Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J. Magn. Reson. 112, 275–279 (1995).
58. H. Matsushita, A. Hosoi, S. Ueha, J. Abe, N. Fujieda, M. Tomura, R. Maekawa, K. Matsushima, O. Ohara, K. Kakimi, Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN-dependent cell-cycle arrest. Cancer Immunol. Res. 3, 26–36 (2015).
59. D. C. Palmer, C.-C. Chan, L. Gattinoni, C. Wrzesinski, C. M. Paulos, C. S. Hinrichs, D. J. Powell Jr., C. A. Klebanoff, S. E. Finkelstein, R. N. Fariss, Z. Yu, R. B. Nussenblatt, S. A. Rosenberg, N. P. Restifo, Effective tumor treatment targeting a melanoma/ melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 105, 8061–8066 (2008).
60. E. W. Su, C. J. Moore, S. Suriano, C. B. Johnson, N. Songalia, A. Patterson, D. J. Neitzke, K. Andrijauskaite, E. Garrett-Mayer, S. Mehrotra, C. M. Paulos, A. L. Doedens, A. W. Goldrath, Z. Li, D. J. Cole, M. P. Rubinstein, IL-2R mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci. Transl. Med. 7, 311ra170 (2015).